{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T16:32:59Z","timestamp":1757608379826,"version":"3.44.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,18]]},"DOI":"10.1093\/skinhd\/vzae010","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T11:02:38Z","timestamp":1737543758000},"page":"82-87","source":"Crossref","is-referenced-by-count":0,"title":["Favourable response of Blaschko linear psoriasis to interleukin-23 inhibition"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6680-7857","authenticated-orcid":false,"given":"Jeremias L K","family":"Reich","sequence":"first","affiliation":[{"name":"Oxford University Clinical Academic Graduate School, Oxford University , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5026-0431","authenticated-orcid":false,"given":"Alexandros","family":"Onoufriadis","sequence":"additional","affiliation":[{"name":"Laboratory of Medical Biology and Genetics, School of Medicine, Aristotle University of Thessaloniki , Thessaloniki ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3708-9964","authenticated-orcid":false,"given":"John A","family":"McGrath","sequence":"additional","affiliation":[{"name":"School of Basic and Medical Biosciences, St John\u2019s Institute of Dermatology, King\u2019s College London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-4332","authenticated-orcid":false,"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[{"name":"Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf , Hamburg ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"2025090300365746300_vzae010-B1","doi-asserted-by":"crossref","first-page":"15382","DOI":"10.1038\/ncomms15382","article-title":"Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants","volume":"8","author":"Tsoi","year":"2017","journal-title":"Nat Commun"},{"key":"2025090300365746300_vzae010-B2","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/ng.694","article-title":"A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1","volume":"42","author":"Genetic Analysis of Psoriasis Consortium & the Wellcome Trust Case Control Consortium 2","year":"2010","journal-title":"Nat Genet"},{"key":"2025090300365746300_vzae010-B3","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.4049\/jimmunol.2100686","article-title":"ERAP1 controls the autoimmune response against melanocytes in psoriasis by generating the melanocyte autoantigen and regulating its amount for HLA-C*06:02 presentation","volume":"207","author":"Arakawa","year":"2021","journal-title":"J Immunol"},{"key":"2025090300365746300_vzae010-B4","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"2025090300365746300_vzae010-B5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jamadermatol.2019.0098","article-title":"Association of HLA-C*06:02 status with differential response to ustekinumab in patients with psoriasis: a systematic review and meta-analysis","volume":"155","author":"van Vugt","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2025090300365746300_vzae010-B6","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/bjd.18013","article-title":"Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: results from extension phase of the SUPREME study","volume":"181","author":"Papini","year":"2019","journal-title":"Br J Dermatol"},{"key":"2025090300365746300_vzae010-B7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/jmg.28.5.337","article-title":"Somatic recombination may explain linear psoriasis","volume":"28","author":"Happle","year":"1991","journal-title":"J Med Genet"},{"key":"2025090300365746300_vzae010-B8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jid.2021.07.007","article-title":"Transcriptomic analysis of Blaschko-linear psoriasis reveals shared and distinct features with psoriasis vulgaris","volume":"142","author":"Onoufriadis","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2025090300365746300_vzae010-B9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s40257-018-0354-9","article-title":"Clinical and therapeutic aspects of linear psoriasis: a study of 30 cases","volume":"19","author":"Say","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"2025090300365746300_vzae010-B10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1684\/ejd.2013.2150","article-title":"Blaschko-linear manifestations of polygenic inflammatory diseases: analysis of 17 cases","volume":"23","author":"Lenormand","year":"2013","journal-title":"Eur J Dermatol"},{"key":"2025090300365746300_vzae010-B11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med"},{"key":"2025090300365746300_vzae010-B12","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab","volume":"141","author":"Mehta","year":"2021","journal-title":"J Invest Dermatol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/5\/1\/82\/61559648\/vzae010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/5\/1\/82\/61559648\/vzae010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T04:37:04Z","timestamp":1756874224000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/5\/1\/82\/7972519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,22]]},"published-print":{"date-parts":[[2025,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzae010","relation":{},"ISSN":["2690-442X"],"issn-type":[{"type":"electronic","value":"2690-442X"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,1,22]]}}}